Dr. Reddy’s says Avigan effective against COVID-19 symptoms

Healthcare solutions provider Global Response Aid (GRA) and Dr. Reddy’s Lab (RDY) say that the anti-viral drug Avigan demonstrated ‘promising’ results against COVID-19, from a Phase 3 study conducted in Japan with the sponsorship of FujiFilm Toyama Chemical.

Analysis from 156 hospitalized patients showed that patients who received Avigan recovered from COVID-19 symptoms 2.8 days earlier, on average, compared with the control group.

Avigan, contains the active ingredient Favipiravir, was developed by FujiFilm Toyama Chemical as an anti-influenza drug. It is undergoing testing in the U.S. in a Phase 2 study involving initially hospitalized COVID-19 patients, sponsored by FujiFilm Toyama Chemical, as well as an investigator-initiated Phase 2 study in mild or asymptomatic COVID-19 subjects conducted by the Stanford University School of Medicine.

Avigan Tablet was approved in Japan in 2014 as an influenza anti-viral drug.

GRA, Dr. Reddy’s, and FujiFilm Toyama recently entered into a licensing agreement for Avigan.

https://seekingalpha.com/news/3616524-dr-reddys-says-avigan-effective-against-covidminus-19-symptoms